← Leaderboards
Evanthia Galanis
Mayo Clinic Rochester
$13,573,895
Attributed
$15,569,280
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $23.3M · FY2005–25$25M$18.8M$12.5M$6.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$84,515,648 · 20
By mechanism
U10$32,333,183 · 1
UG1$29,055,267 · 1
U19$7,619,904 · 2
R01$7,470,348 · 4
P50$5,673,576 · 4
R21$995,618 · 2
Top collaborators
- Olwen Hahn10 shared
- Kah-Whye Peng9 shared
- Ranjit Bindra7 shared
- Jann N Sarkaria7 shared
- Electra D. Paskett5 shared
- Steven Piantadosi5 shared
- Antonio M Omuro4 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Kah-Whye Peng$11,311,466
- Jamie N Bakkum-Gamez$820,154
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationMeasles VirusMalignant NeoplasmsViralTumorCancer TherapyPre-ClinicalBaseCellsOncolyticClinical TrialsGenesAnimal ModelRecurrenceEngineeringClinicSafetyCd46 AntigenVirusNeoplastic CellNovel TherapeuticsTranslatingMeaslesCancer Patient
Grant awards (75)
Alliance for Clinical Trials in Oncology Operations Center - GY11 Funded Extension$11,813,476
U10 · FY2025 · CA
Alliance NCORP Research Base$7,877,673
UG1 · FY2025 · CA
Center of Innovation for Brain Tumor Therapeutics$1,203,578
U19 · FY2025 · CA
Alliance for Clinical Trials in Oncology Operations Center - GY11 BIQSFP Funded Extension$623,526
U10 · FY2025 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment$334,372
R01 · FY2025 · CA · contact PI
Alliance NCORP Research Base$10,618,485
UG1 · FY2024 · CA
Alliance for Clinical Trials in Oncology Operations Center$9,189,885
U10 · FY2024 · CA
Center of Innovation for Brain Tumor Therapeutics$1,861,663
U19 · FY2024 · CA
Alliance for Clinical Trials in Oncology Operations Center - GY11 BIQSFP Supplements$1,172,342
U10 · FY2024 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment$412,267
R01 · FY2024 · CA · contact PI
Alliance NCORP Research Base - BIQSFP A211901 GY11 Supplement$34,456
UG1 · FY2024 · CA
Alliance NCORP Research Base - BIQSFP GY11 Supplements$6,811
UG1 · FY2024 · CA
Alliance NCORP Research Base$10,517,842
UG1 · FY2023 · CA
Alliance for Clinical Trials in Oncology Operations Center$9,533,954
U10 · FY2023 · CA
Center of Innovation for Brain Tumor Therapeutics$1,999,213
U19 · FY2023 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment$456,968
R01 · FY2023 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,187,659
U19 · FY2022 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment$351,804
R01 · FY2022 · CA · contact PI
Admin-Core-001$61,986
U19 · FY2022 · CA
Center of Innovation for Brain Tumor Therapeutics - Diversity Supplement$61,986
U19 · FY2022 · CA
Center of Innovation for Brain Tumor Therapeutics$1,243,819
U19 · FY2021 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment$354,017
R01 · FY2021 · CA · contact PI
Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer$225,862
P50 · FY2021 · CA · contact PI
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers$584,773
R01 · FY2020 · CA · contact PI
Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer$280,992
P50 · FY2020 · CA · contact PI
Gene and Virus Therapy Program$45,693
P30 · FY2020 · CA · contact PI
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers$596,069
R01 · FY2019 · CA · contact PI
Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer$268,085
P50 · FY2019 · CA · contact PI
Gene and Virus Therapy Program$16,215
P30 · FY2019 · CA · contact PI
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers$592,664
R01 · FY2018 · CA · contact PI
Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer$308,925
P50 · FY2018 · CA · contact PI
Gene and Virus Therapy Program$143,844
P30 · FY2018 · CA · contact PI
Gene and Virus Therapy Program$7,439
P30 · FY2018 · CA · contact PI
Gene and Virus Therapy Program$6,548
P30 · FY2018 · CA · contact PI
Gene and Virus Therapy Program$2,609
P30 · FY2018 · CA · contact PI
Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers$509,698
R01 · FY2017 · CA · contact PI
Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer$287,712
P50 · FY2017 · CA · contact PI
Gene and Virus Therapy Program$145,342
P30 · FY2017 · CA · contact PI
Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancer$282,326
P50 · FY2016 · CA · contact PI
Gene and Virus Therapy Program$143,842
P30 · FY2016 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Gliomas$210,893
P50 · FY2015 · CA · contact PI
Gene and Virus Therapy Program$145,221
P30 · FY2015 · CA · contact PI
Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas$318,329
R01 · FY2014 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Gliomas$286,203
P50 · FY2014 · CA · contact PI
Gene and Virus Therapy Program$143,793
P30 · FY2014 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$393,649
P50 · FY2013 · CA · contact PI
Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas$309,001
R01 · FY2013 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Gliomas$211,214
P50 · FY2013 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$507,051
R01 · FY2012 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$372,958
P50 · FY2012 · CA · contact PI
Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas$330,711
R01 · FY2012 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Gliomas$247,437
P50 · FY2012 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$424,154
R01 · FY2011 · CA
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$344,948
P50 · FY2011 · CA · contact PI
Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas$328,355
R01 · FY2011 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$530,593
R01 · FY2010 · CA
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$396,237
P50 · FY2010 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer$529,522
R01 · FY2009 · CA · contact PI
Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer$398,680
P50 · FY2009 · CA · contact PI
Targeted MV-CEA as a Potent Antitumor Agent against GBM$274,376
P50 · FY2008 · CA · contact PI
Targeted MV-CEA as a Potent Antitumor Agent against GBM$290,159
P50 · FY2007 · CA · contact PI
Measles Virotherapy for Glioblastoma Multiforme$224,632
R21 · FY2007 · CA · contact PI
Targeted MV-CEA as a Potent Antitumor Agent against GBM$295,480
P50 · FY2006 · CA · contact PI
Measles Virotherapy for Glioblastoma Multiforme$232,254
R21 · FY2006 · CA · contact PI
Targeted MV-CEA as a Potent Antitumor Agent against GBM$160,721
P50 · FY2005 · CA
INTRAPERITONEAL ADMINISTRATION OF A STRAIN OF MEASLES VIRUS IN OVARIAN CA$15,402
M01 · FY2005 · RR
Measles Virus Therapy for Ovarian Cancer$269,366
R21 · FY2004 · CA
Targeted MV-CEA as a Potent Antitumor Agent against GBM$136,719
P50 · FY2004 · CA
FUSOGENIC MEMBRANE PROTEINS AS THERAPEUTIC TRANSGENES$114,588
K08 · FY2004 · CA
Phase II Trial of CCI-779 in Recurrent Glioblastoma$464
M01 · FY2004 · RR
Measles Virus Therapy for Ovarian Cancer$269,366
R21 · FY2003 · CA
FUSOGENIC MEMBRANE PROTEINS AS THERAPEUTIC TRANSGENES$114,588
K08 · FY2003 · CA
FUSOGENIC MEMBRANE PROTEINS AS THERAPEUTIC TRANSGENES$114,588
K08 · FY2002 · CA
FUSOGENIC MEMBRANE PROTEINS AS THERAPEUTIC TRANSGENES$103,788
K08 · FY2001 · CA
FUSOGENIC MEMBRANE PROTEINS AS THERAPEUTIC TRANSGENES$103,788
K08 · FY2000 · CA